FDA, DEA Heads Acknowledge ADHD Drug Shortage in Public Letter — Agencies ask manufacturers to boost production, but call on docs to prescribe appropriately
In a letter to the American public, the heads of the Drug Enforcement Administration (DEA) and FDA acknowledged ongoing stimulant drug shortages and recounted their initiatives to improve access -- while calling for efforts to diminish potential overuse and misuse of these powerful medications.
Other Articles in this Edition
ADHD: Study finds that noninvasive brain stimulation treatment can ease symptoms
Mitochondrial Dysfunction May Be Important Biomarker for ADHD, ASD
Micro-cognition biomarkers redefine ADHD subtypes
COVID-19 led to increased anxiety for families with children with neurodevelopmental conditions
ADHD in an era of distraction: Why are more adults getting diagnosed?
ADD vs ADHD: What Are the Differences? Understanding the Types and Signs in Kids and Adults
3 Big Mistakes Parents Of Kids With ADHD Make — And How To Avoid Them
Stretching Your Dollar: How to Overcome Debt While Living With ADHD
UK children waiting 16 months on average for ADHD and autism screening – study